Avaleht › Müeloom › Maryland › Baltimore
Müeloom kliinilised uuringud linnas Baltimore, MD
13 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas Baltimore ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 3
- Johns Hopkins Hospital, Baltimore
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 3
- University of Maryland School of Medicine, Baltimore
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
VärbamineFaas 3
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
VärbamineVarajane 1. faas
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
VärbamineFaas 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Collection of Tissue Samples for Cancer Research
VärbamineVaatlusuuring
- Johns Hopkins University, Baltimore
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
VärbamineFaas 3
- University of Maryland | Greenebaum Cancer Center, Baltimore
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
VärbamineFaas 3
- Research Site, Baltimore
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
VärbamineFaas 1
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
VärbamineFaas 3
- Greater Baltimore Medical Center, Baltimore
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
VärbamineFaas 3
- Greenebaum Cancer Center UM of MD, Baltimore
- John Hopkins, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
VärbamineFaas 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1/2
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Durham, NC37 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
Muud uuringud linnas Baltimore
- Mitteväikerakuline kopsuvähk60 uuringut
- Rinnavähk47 uuringut
- Eesnäärmevähk43 uuringut
- Kopsuvähk40 uuringut
- Vähk (kõik liigid)37 uuringut
- Käär- ja pärasoolevähk31 uuringut
- Pankreasevähk31 uuringut
- Metastaatiline vähk28 uuringut
- Rasvumine25 uuringut
- Südamepuudulikkus24 uuringut
- Põievähk24 uuringut
- Insult22 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.